SWM
XENE icon

Spire Wealth Management’s Xenon Pharmaceuticals XENE Stock Holding History

Spire Wealth Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$6.26K – 2501
2025
Q2 		$6.26K Hold
200
– – ﹤0.01% 1880
2025
Q1 		$6.71K Hold
200
– – ﹤0.01% 1978
2024
Q4 		$7.84K Buy
+200
New +$8.27K ﹤0.01% 1911

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Spire Wealth Management's XENE Position: Q3 2025 in Review

Spire Wealth Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 200 shares — an estimated $6.26K sold.

Spire Wealth Management first reported a position in XENE in Q4 2024 and held it in 3 quarters. The position peaked at $7.84K in Q4 2024. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

  • Spire Wealth Management reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Spire Wealth Management sold 200 Xenon Pharmaceuticals shares in Q3 2025, an estimated $6.26K.
  • Spire Wealth Management first reported a position in Xenon Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Spire Wealth Management's Xenon Pharmaceuticals position peaked at $7.84K in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Spire Wealth Management's 13F filing for Q3 2025, filed 23 Oct 2025.